Synergistic Herbal Composition for Lung Cancer Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies lack specificity, often affecting normal cells and there is a need for herbal compositions with synergistic anti-cancer activity that can target cancer cells without harming other body cells, particularly for non-small cell lung carcinoma.
Innovation Solution
A synergistic pharmaceutical composition comprising compounds Neo-isopulegol, Iso-pulegol, and Citronellol in a 1:1:1 ratio, derived from Litsea cubeba seeds, administered in vapor form to induce apoptosis in lung cancer cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current anti-cancer therapies are used, then cancer cells are targeted, but normal cells are also affected causing harmful side effects
Solution Approach 1:
The patent segments the anti-cancer therapy into three distinct compounds (C2 neo-isopulegol, C3 iso-pulegol, and C4 citronellol) that work synergistically. Each compound targets cancer cells through different mechanisms, allowing selective toxicity toward cancer cells while sparing normal cells. This segmentation enables precise targeting of cancer pathways without affecting normal cellular functions.
Solution Approach 2:
The composition exhibits local quality by demonstrating selective cytotoxicity - it is highly effective against cancer cells (A-549 line) while showing minimal to no toxicity toward normal cells (hepatocytes, adipocytes, skeletal muscle cells). This localized effect is achieved through the specific biochemical properties of C2, C3, and C4 that interact preferentially with cancer cell pathways.
2Device complexity
If single compound anti-cancer drugs are used, then treatment is simple, but resistance develops and efficacy decreases
Solution Approach 1:
The patent merges three compounds (C2 neo-isopulegol, C3 iso-pulegol, and C4 citronellol) into a single synergistic composition. The combination exhibits enhanced anti-cancer activity compared to individual compounds, with the trio working together to target multiple cancer pathways simultaneously, preventing resistance development while maintaining manageable complexity.
Solution Approach 2:
The invention creates a composite pharmaceutical composition where C2, C3, and C4 work together synergistically. This composite approach combines compounds with complementary mechanisms of action, achieving superior anti-cancer efficacy that exceeds the sum of individual compound effects, while addressing the limitation of single-agent therapies.
3Object-affected harmful factors
If systemic anti-cancer treatment is administered, then cancer cells are reached, but healthy tissues are damaged
Solution Approach 1:
The composition exhibits local quality by demonstrating selective cytotoxicity - it is highly effective against cancer cells (A-549 line) while showing minimal to no toxicity toward normal cells (hepatocytes, adipocytes, skeletal muscle cells). This localized effect is achieved through the specific biochemical properties of C2, C3, and C4 that interact preferentially with cancer cell pathways.
4Productivity
If high concentration of anti-cancer agent is used, then cell death increases, but toxicity to normal cells increases
Solution Approach 1:
The patent segments the anti-cancer therapy into three distinct compounds (C2 neo-isopulegol, C3 iso-pulegol, and C4 citronellol) that work synergistically. Each compound targets cancer cells through different mechanisms, allowing selective toxicity toward cancer cells while sparing normal cells. This segmentation enables precise targeting of cancer pathways without affecting normal cellular functions.
Solution Approach 2:
The invention utilizes parameter changes by optimizing the concentration ratios and combinations of C2, C3, and C4 to achieve maximum cancer cell killing at low overall concentrations. The synergistic interaction allows the composition to achieve 90% cancer cell death at concentrations that are non-toxic to normal cells, representing a significant improvement in the therapeutic window.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively induces cell cycle arrest and apoptosis in lung cancer cells, achieving a 90%±5.6% cell death rate with minimal impact on normal cells, and can be delivered via inhalation due to its vapor form.
Implementation Method 1
administered in vapor form to induce apoptosis in lung cancer cells
Implementation Method 2
can be delivered via inhalation due to its vapor form
Data Source
AI summary
The present invention relates to a synergistic pharmaceutical composition comprising Compound C2 (Neo-isopulegol), C3 (Iso-pulegol) and C4 (Citronellol) derived from herbal seed extract of Litsea cubeba useful for the treatment of lung cancer. The present invention also relates to the activity of compounds C2 or C3 or C4 either alone or in combination in killing of A549 lung cancer cells.